Objective: Data on long-term use of secondary prevention medications following stroke are limited. The Adherence eValuation After Ischemic stroke-Longitudinal (AVAIL) Registry assessed patient, provider, and system-level factors influencing continuation of prevention medications for 1 year following stroke hospitalization discharge.
Nearly 700,000 persons have ischemic strokes in the United States each year, and about 160,000 of these events are recurrent. 1 Several classes of medications are effective in modifying stroke risk factors and preventing stroke recurrence. 1, 2 Although continuing prescribed medications is key to improving patient outcomes, medication use commonly declines over time, 3 leading to potentially avoidable stroke recurrence, disability, and death. 4 Prior studies have identified multiple barriers to long-term continuation of medications including inadequate care transitions, side effects, poor patient-provider communication, suboptimal patient resources, and medication affordability, as well as inadequate provider knowledge of drug costs and insurance coverage. 5 Information on longitudinal medication use and the reasons for medication discontinuation in stroke patients is limited.
The aim of the Adherence eValuation After Ischemic stroke-Longitudinal (AVAIL) Registry was to measure secondary prevention medication regimen persistence from discharge to 12 months in a nationwide sample of patients from hospitals participating in the American Heart Association/American Stroke Association-administered Get With The Guidelines SM -Stroke program (GWTG-Stroke). This study sought to determine 1) rates of medication use at 12 months, 2) reasons for medication discontinuation, and 3) patient, provider, and system-level factors associated with medication use or nonuse.
METHODS
The study design and methods of the AVAIL registry program has been published previously. 6 Participants were eligible for this observational cohort study if they were age 18 years or older, hospitalized for a primary diagnosis of acute ischemic stroke or TIA, directly admitted based on physician evaluation or arrival through the emergency department, provided consent to participate, and their data were collected as part of the GWTG-Stroke TM Program. The recruitment period for this study was July 2006 through July 2008, and follow-up was completed October 2009. Sample size was estimated at 3,000 and the number was based on feasibility of enrollment in this multicenter study and not a power calculation.
Trained multilingual interviewers from the Duke Clinical Research Institute (DCRI) contacted AVAIL participants 3 and 12 months after hospital discharge. For patients who could not respond because of illness severity, speech or language deficits, or death, interviewers attempted to speak with an informed proxy, such as a family member or caregiver. Proxy respondents were not asked to provide subjective data on the patient's perceived functional status, medication knowledge, or satisfaction with provider communications. A patient was classified as lost to follow-up only after multiple contact attempts were unsuccessful and the time from discharge was more than 639 days (or 274 days after 12-month anniversary of discharge), or the subject/ proxy refused.
Medication continuation was ascertained by comparing hospital discharge medications (faxed to the coordination center) with the current medications reported by the patient/proxy. Patients who reported discontinuing a medication were asked whether they chose to stop the medication or were instructed to do so by a health care provider. If discontinuation was self-initiated, patients were asked to select a response that most closely reflected the reason: side-effects, cost, medication not helping, or other.
Persistence is generally defined as duration of therapy, whereas adherence refers to the extent at which patients take medications as prescribed by their providers. 7, 8 In AVAIL, 12month persistence was defined as continuation of all secondary preventive medications prescribed at hospital discharge, and adherence as continuation of prescribed medications except those stopped according to health care provider instructions. 7 Patients were considered nonpersistent if they discontinued a medication regardless of the reason, and nonadherent if they discontinued a medication for reasons other than provider recommendation. The primary outcome, regimen persistence, was analyzed as an all-or-none variable (i.e., subjects who remained on all discharge medication classes at the 12-month follow-up were considered persistent, regimen persistence ϭ 1, whereas subjects who stopped at least one class of medication prescribed at discharge were nonpersistent, regimen persistence ϭ 0). Composite persistence was defined as the percentage (0% to 100%) of discharge medication classes that subjects reported taking at 12 months.
Outcome Sciences, Inc., serves as the data collection and coordination center for the initial in-hospital data collection via GWTG. The DCRI serves as the data analysis center for both GWTG-Stroke and AVAIL and has an agreement to analyze the aggregate deidentified data for research purposes.
Standard protocol approvals, registrations, and patient consents. Each participating site obtained institutional review board approval before screening subjects for AVAIL. Written informed consent was obtained from all patients (or guardians of patients) participating in the study.
Statistical analysis.
To be eligible for determination of persistence and adherence, documentation of being on a specific medication or class of medication at discharge was required. Persistence was determined for the following 5 medication classes: warfarin, antiplatelet, antihypertensive, lipid-lowering, and diabetes medications. Both regimen and composite persistence scores were used to summarize class-level persistence. Subjects for whom data were missing for one or more medication classes were not included in this analysis (n ϭ 14).
Contingency tables were generated to explore the relationship between 12-month regimen persistence and patient characteristics, provider factors, and hospital-level characteristics. For these analyses, data were analyzed for all patients (including proxy responders) and repeated for self-responders only. Continuous variables are presented as medians with interquartile ranges and categorical variables are expressed as frequencies with percentages. The Wilcoxon rank sum test was used for continuous variables and Pearson 2 test was used for categorical variables to evaluate the associations between regimen persistence and patient and hospital characteristics.
A multivariable logistic regression model was used to further evaluate the influence or confounding of demographic, clinical, and other factors on 12-month regimen persistence and included the following prespecified covariates: patient baseline characteristics including age, gender, race/ethnicity, marital status, living situation, education level, work status, household income, medical history, discharge destination, ambulatory status, and number of discharge medications. Additional potential covariates included whether patients had received medical instruction, if and how they tracked medication use, medication cost, insurance coverage, whether they had a follow-up appointment with a provider, modified Rankin Scale (mRS) score, and rehabilitation utilization. Hospital characteristics included size, type, and geographic region. The same covariates were used in a logistic regression model to evaluate factors affecting adherence.
We also determined whether medication regimen persistence varied based on whether the survey responses were provided by the subject or a proxy. The self-responders were then analyzed as a subpopulation separate from the proxy responders. In addition to the previous list, the "subject only" information included understanding of medication purpose and side effects, provider communication perceptions, EuroQOL-5D (EQ5D) 9 quality of life scale, and Patient Health Questionnaire-8 (PHQ8) 10 depression scale. The PHQ-8 excludes a question about suicidality, but nearly identical scoring thresholds for depression severity can be used for the PHQ-9 and PHQ-8. 10 Missing data were imputed to the most popular category or based on clinical perspective (except for hospital characteristics for which missing data were excluded). A backward selection procedure was used to eliminate insignificant factors. The final models included potential predictors with a p value of Ͻ0.10. Likelihood ratios were used to determine the different model results based on a full model vs the backward elimination model. The Generalized Estimating Equation method with exchangeable working correlation structure was used to account for within-hospital clustering. Odds ratios and 95% confidence intervals were calculated. All p values are 2-sided tests. Due to the exploratory nature of our analysis, the p values for the primary outcome were not adjusted for multiple testing. All statistical analyses were performed by the DCRI using SAS software (version 9.2, SAS Institute, Cary, NC).
RESULTS
A total of 3,068 stroke patients from 106 sites were assessed for eligibility for the AVAIL Registry. A total of 188 (6.1%) were excluded because they did not meet inclusion criteria, leaving 2,880 patients. Reasons for exclusions from the analysis are listed in the figure, leaving a final sample size of 2,457 patients. Eight percent were lost to follow-up at 12 months (229/2,880), and the median time to the 12-month interview was 396 days.
Regimen persistence for secondary prevention medications at 12 months was 65.6%. Selfresponders reported higher persistence than patients for whom a proxy was the respondent. Of the 365 questionnaires completed by a proxy at 12 months, 195 (53.4%) reported persistence for the subject at 12 months vs 68.1% self-reported regimen persistence ( p Ͻ 0.0001).
Patient-level variables associated with 12-month persistence are shown in table 1. Factors associated with 12-month persistence included a history of hypertension or dyslipidemia, fewer discharge medications, having an adequate income, 3-month persistence, a follow-up appointment with a neurologist, and overall satisfaction with provider communications.
The percentage of patients prescribed medications by class and by type at discharge, 12-month persistence, and percentage discontinued for each (physician's recommendation, self-discontinued, or reason not otherwise specified) are given in table 2. By medication class, 12-month persistence was highest for antihypertensive medications (87.9%), followed by antiplatelet (87.1%), diabetes (82.3%), lipid-lowering (77.6%), and warfarin (68.2%) medications. The most common reason for nonpersistence was discontinuation by the health care provider, although percentages varied widely by drug class.
The all-or-none adherence at 1 year was 86.6%. By medication category, adherence ranged from 94.8% for antiplatelet therapy to 90.7% for lipidlowering medications (table 2) .
The percentage of missing covariates was low (Ͻ2%) for both logistic regression models. The multivariable predictors of persistence and adherence are given in table 3. Patient age, history of hypertension, history of dyslipidemia, those with less than a college level of education, and mRS Ͻ3 were independent predictors of 12-month persistence, with a trend toward persistence for those with a history of smoking ( p ϭ 0.066) and pillbox use to keep track of medications ( p ϭ 0.062). Additional factors associated with 12-month persistence included having an appointment with a primary care provider (PCP) or a neurologist before the 3-month follow-up, having an adequate income to meet the needs of the household, receiving either inpatient (odds ratio [OR] 0.57, 95% confidence interval [CI] 0.43-0.76) or outpatient (OR 0.76, 95% CI 0.65-0.89) rehabilitation, and discharge from a nonacademic (vs academic) hospital. Findings were similar if the analysis was re- stricted to self-responders (table e-1 on the Neurology ® Web site at www.neurology.org). The multivariable model of adherence was similar to persistence (table 3) , including associations with fewer medications at discharge, having an adequate income, mRS, and having an appointment with a PCP. Factors associated with adherence but not persistence included pillbox use, medication insurance, having received medication instructions, being married, and being discharge to home.
DISCUSSION
The risk of recurrent stroke is 15% over 5 years and highest in the first 6 months after the index stroke, emphasizing the need for early initiation of appropriate prevention therapies. 11 We found that although up to one-third of stroke patients discontinued evidence-based medications prescribed at hospital discharge within 1 year, the majority did so based on postdischarge health care provider recommendations. We cannot determine the appropriateness of these recommendations as there are a variety of justifiable reasons prompting a provider to stop a medication or class of medications, and providers were not interviewed. We did, however, identify several provider-and systemrelated factors that were associated with long-term medication persistence that might be amenable to modification.
The results of previous studies evaluating poststroke secondary prevention medication persistence vary widely. The Riks-Stroke Register in Sweden found persistence by medication categories at 2 years postdischarge (e.g., 56% for statins, 74% for antihypertensive drugs) that was in the range of the AVAIL 1-year regimen persistence. 3 Because the Swedish registry assessed persistence based on pharmacy refills, and because of differences in health care delivery systems, factors associated with persistence differed from those found in AVAIL and included advanced age, institutional living at follow-up, absence of low mood, treatment in a stroke unit, presence of diabetes and atrial fibrillation, and good self-perceived health. 3 Other studies, such as the Preventing Recurrence Of Thromboembolic Events through Coordinated Treatment (PROTECT) study, report higher persistence rates. 12 PROTECT, however, was a single-center quality improvement initiative that focused on evidence-based tools and algorithms for stroke prevention strategies. At 1 year of follow-up of 128 patients, antithrombotic use was maintained in 98%, statins in 99%, angiotensin converting enzyme inhibitors/angiotensin receptor blockers in 89%, and thiazide diuretics in 82%. 12 In another study, stroke patients in Nova Scotia, Canada, had a self-reported persistence of Ͼ90% for all categories of stroke prevention medications. 13 In AVAIL, longitudinal assessment of prevention regimen all-or-none persistence decreased from 76% at 3 months 14 to 66% at 1 year. This decline is consistent with the findings of other studies. 3 For individual drug classes in AVAIL, 1-year persistence was 68.2% (warfarin) to 87.9% (antihypertensive medications) and adherence was 85% to 95% for these medication classes.
Several baseline factors, such as age, medical history, and education level, predicted long-term persistence. The presence of a cardiovascular diagnosis prestroke may mean fewer changes in medications at discharge and it is possible that familiarity with the medications may aid in longer-term persistence. There was an inverse relationship between college education and long-term persistence, although this was not associated with adherence. One possible explanation for this observation is that more educated stroke patients may research their medications and provide reasons to their provider that mutually led to discontinuation of a medication.
In the AVAIL cohort, understanding why medications are taken as well as a reported understanding of potential side effects were significant predictors of persistence. This may be because these patients are better able to weigh the risks vs benefits of a medication as compared with patients who have a poorer understand-ing of their treatments. Using a pillbox or other tool to track medications was associated with better persistence and adherence, highlighting the importance of reminders and organized pill-taking. Receiving instructions about their medications was associated with better adherence but not persistence. This is expected as persistence does not reflect health care provider instructions to stop a medication after the initial prescription.
Self-reported financial variables were associated with both long-term persistence and adherence. AVAIL participants were asked if their household income adequately met their needs in general; those who responded "adequately" or "more than adequately" were 30% more likely to be persistent and nearly 50% more likely to be adherent (table 3) . Having insurance coverage for medication costs was also associated with about a 60% higher likelihood of adherence.
Health care provider discontinuation was the most common reason for nonpersistence in AVAIL. The rate of nonadherence was 14% as compared to 34% for nonpersistence. Based on the number of patients reclassified, it seems that provider discontinuation occurred across multiple medication classes in different patients. Because we did not contact providers, we cannot determine the reasons these providers discontinued a specific medication. A study of evidence-based cardiovascular medication persistence in patients with acute coronary syndromes reported that provider discontinuation of medications increased with patient age. 15 Further examination of the reasons for medication nonpersistence from both the provider and patient perspectives in stroke patients is needed.
In the AVAIL cohort, an appointment with a PCP (as opposed to merely having a PCP) was associated with a 47% increase in 1-year persistence; an appointment with a neurologist was associated with persistence to a lesser degree (table 3) . Contact with a physician provides both the opportunity to obtain prescription refills and for patients to communicate information about their condition and any medication concerns. This is not only important for medication persistence; in a study of Medicaid patients in Tennessee, ambulatory care visits were associated with decreased mortality in patients with hypertension. 16 Another provider-level influence on long-term persistence is a lower number of medications at discharge. Persistence increased by 4% for each decrease in the number of prescribed medications. This is consistent with a study of Medicare enrollees and cardiovascular disease medication refill adherence, which reported that a regimen of more than 2 medications was independently predictive of poor refill adherence as compared to less than 3 medications. 17 For hypertension, the use of simplified antihypertensive medications (such as fixed-dose combinations of drugs in a single pill) was associated with greater adherence in a high-risk Medicaid population. 18 Stroke patients participating in rehabilitation programs may have more changes in their medications because rehabilitation requires frequent contact with health care providers. The inpatient rehabilitation setting, in particular, is an opportunity to change medications prescribed at hospital discharge to different ones that may be better tolerated while on the rehabilitation unit. Because medication changes during inpatient are made based on health care provider orders, rehabilitation was not independently associated with adherence (table 3) .
The AVAIL Registry has several strengths: it is one of the largest registries outside of a clinical trial of medication use focused on stroke patients. The AVAIL Registry includes assessments of known barriers related to patient, provider, and system-level factors affecting medication persistence/adherence. AVAIL has several limitations. AVAIL subjects were hospitalized in GWTG-Stroke sites having ongoing quality improvement programs; AVAIL results may not be generalizable to patients hospitalized in non-GWTG hospitals. These analyses were exploratory, and because of the backward selection method of model building, the interpretation of the individual variable's association with the outcome is limited. The C indices reflect relatively poor model performance. In addition, persistence and adherence were obtained through self-report and not independently audited by pill counts or otherwise validated. Other large studies, such as the Prospective Registry Evaluating Myocardial Infarction: Events and Recovery (PREMIER), 19 utilized self-reported adherence. In other settings, self-report generally agrees with pharmacy claims data, 20 and is the best method to ascertain reasons for nonpersistence. 21 We did not independently review medical records or measure prevention treatment endpoints and therefore cannot determine adequate risk factor control. Although we might assume an association between medication persistence/adherence and recurrent stroke, we were unable to analyze this association because events may have occurred prior to the assessment of the 3-and 12-month medication use.
The AVAIL study showed that there are several factors predictive of long-term stroke prevention medication persistence and adherence including patient, provider, and system level factors. Given the complex aspects of medication-taking behavior, future interventions will likely require multifaceted approaches with involvement of the patient, caregiver, hospital and primary care providers, pharmacists, and insurers in order to effectively improve medication persistence and adherence. Abbreviations: CI ϭ confidence interval; OR ϭ odds ratio; PCP ϭ primary care provider. a Multiple regression models of 12-month persistence (for total population of subject and proxy responder, n ϭ 2,457; C index ϭ 0.64), and 12-month adherence, defined as persistent if physician discontinued (n ϭ 2,457; C index 0.69). Models adjusted for age, sex, race: black vs other, stroke type, previous stroke/TIA, coronary artery disease/prior myocardial infarction, carotid stenosis, diabetes, peripheral vascular disease, hypertension, dyslipidemia, and smoking.
